ClinicalTrials.Veeva

Menu

COVID-19 Induced Telogen Effluvium

I

Istanbul Medeniyet University

Status

Unknown

Conditions

Alopecia
Telogen Effluvium
SARS-CoV Infection
Covid19

Treatments

Diagnostic Test: Blood Tests

Study type

Observational

Funder types

Other

Identifiers

NCT04834102
2021/0123

Details and patient eligibility

About

This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection

Full description

Telogen effluvium (TE) is one of the most common causes of non-scarring alopecia. During the COVİD-19 pandemic, there is an increased number of Telogen effluvium patients.This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection and correlation between the severity of covid-19 and TE.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Sars-CoV-2 infection in the past year

Exclusion criteria

  • Other common causes of Telogen effluvium ( such as anemia, iron deficiency, thyroid dysfunction)

Trial contacts and locations

1

Loading...

Central trial contact

Umut Mert YILDIRIM, Dr.; Hasan AKSOY, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems